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Lymphoid neoplasms form a family of cancers affecting B-cells, T-cells, and NK
cells. The Toll-Like Receptor (TLR) signaling adapter molecule MYD88 is the most
frequently mutated gene in these neoplasms. This signaling adaptor relays signals from
TLRs to downstream effector pathways such as the Nuclear Factor kappa B (NFκB)
and Mitogen Activated Protein Kinase (MAPK) pathways to regulate innate immune
responses. Gain-of-function mutations such as MYD88[L265P] activate downstream
signaling pathways in absence of cognate ligands for TLRs, resulting in increased cellular
proliferation and survival. This article reports an analysis of non-synonymous somatic
mutations found in the TLR signaling network in lymphoid neoplasms. In accordance
with previous reports, mutations map to MYD88 pro-inflammatory signaling and not
TRIF-mediated Type I IFN production. Interestingly, the analysis of somatic mutations
found downstream of the core TLR-signaling network uncovered a strong association
with the ERK1/2 MAPK cascade. In support of this analysis, heterologous expression
of MYD88[L265P] in HEK293 cells led to ERK1/2 MAPK phosphorylation in addition
to NFκB activation. Moreover, this activation is dependent on the protein kinase Tumor
Promoting Locus 2 (TPL2), activated downstream of the IKK complex. Activation of
ERK1/2 would then lead to activation, amongst others, of MYC and hnRNPA1, two
proteins previously shown to contribute to tumor formation in lymphoid neoplasms. Taken
together, this analysis suggests that TLR-mediated ERK1/2 activation via TPL2 may be
a novel path to tumorigenesis. Therefore, the hypothesis proposed is that inhibition of
ERK1/2 MAPK activation would prevent tumor growth downstream of MYD88[L265]. It
will be interesting to test whether pharmacological inhibitors of this pathway show efficacy
in primary tumor cells derived from hematologic malignancies such as Waldenstrom’s
Macroglobulinemia, where the majority of the cells carry the MYD88[L265P] mutation.
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OVERVIEW: THE TOLL-LIKE RECEPTOR
(TLR) SIGNALING ADAPTER MYD88 IS THE
MOST FREQUENTLY MUTATED GENE IN
LYMPHOID NEOPLASMS
The adven Next Generation Sequencing has made available rich
data sources to better understand biological processes. In the
field of cancer, it is now possible to obtain a better idea of the
mutations landscape of specific types of tumors. Analysis of this
information can yield a greater insight into the pathogenesis of
specific disorders. In this Hypothesis and Theory article, we have
mined the Catalog Of Somatic Mutations In Cancer (COSMIC)
to better understand the process of cellular transformation of
lymphocytes (lymphoid neoplasms). We focused on the Toll-
Like Receptor (TLR) signaling pathway as previous evidences
had highlighted an important role in B cell transformation for
MYD88, one of its main downstream signaling adaptor.
MYD88 is mutated in 22% of lymphoid tumor samples
according to the COSMIC database (Sanger institute, UK; Forbes
et al., 2014) (Table 1). This critical signaling adaptor normally
relays signals from TLRs to downstream effector pathways such
as the Nuclear Factor kappa B (NFκB) and Mitogen Activated
Protein Kinase (MAPK) pathways to regulate innate immune
responses (Kawai and Akira, 2010). Gain-of-function mutations
such as MYD88[L265P] activate downstream signaling pathways
in absence of cognate ligands for TLRs, resulting in increased
cellular proliferation, and survival (Yang et al., 2013; Ansell
et al., 2014; Avbelj et al., 2014). The medical and scientific
literature investigating MYD88 role in cancer focuses on NFκB
activation (Treon et al., 2012; Yang et al., 2013). However, TLR-
mediated activation of MYD88 also leads to the activation of
other signaling pathways such as ERK1/2, p38 MAPK, and JNK
(Figure 1). The contribution of these other effector signaling
pathways to tumor formation in the context of TLR-activation
has been largely overlooked and deserves closer attention. In
order to formulate a testable hypothesis on the identity of the
TLR effector pathway(s) driving the tumorigenic process, we
first investigated the frequency of mutations of TLR signaling
components in lymphoid neoplasms.
ANALYSIS OF SOMATIC MUTATIONS
FOUND IN THE TLR SIGNALING
NETWORK IN LYMPHOID NEOPLASM
Overview of the TLR Signaling Network
The TLR family has 10 members in humans (Carpenter and
O’Neill, 2009). Following dimerization, TLRs bind different
adaptor molecules through their Toll/IL-1 receptor domain
(TIR). The family can be sub-divided between receptors signaling
through the adaptors MYD88 (TLR1, TLR2, TLR4, TLR5, TLR6,
TLR7, TLR8, and TLR9) or TRIF (TLR3 and TLR4). MYD88
mediates the sequential recruitment of IL-1R-associated protein
kinases (IRAK) (Muzio et al., 1997; Wesche et al., 1997), TNF-
receptor-associated factor 6 (TRAF6) (Cao et al., 1996) and TGF-
βActivated Kinase (TAK1) (Ninomiya-Tsuji et al., 1999; Lee et al.,
2000). This signaling cascade leads to the activation of four major
signaling pathways: the NFκB pathway and the three MAPK
pathways, ERK1/2, JNK, and p38 MAPK (Figure 1). The TRIF
adaptor, which can be recruited directly to TLR3, or indirectly
via TRAM to TLR4, lead to the production of type I interferons
via the activation of the IKK family members IKKε and TBK1
and the phosphorylation of interferon response factors (IRFs)
(Yamamoto et al., 2002). TRIF can also mediate NFκB activation
via Pellino 1 and RIP1 (Meylan et al., 2004; Chang et al., 2009).
Non-silent Somatic Mutations in the TLR
Pathway
Based on the current literature a TLR signaling network
containing 79 distinct molecules involved in MYD88-
signaling was assembled. A proposed network organization
of these molecules in TLR signaling is illustrated in
Supplementary Figure 1 (Oda and Kitano, 2006; Padwal
et al., 2014). Each of these molecules was investigated for the
presence of non-synonymous somatic mutations in lymphoid
neoplasms using data extracted from the COSMIC database
(Table 1) (Forbes et al., 2014). The search parameters used
were: Tissue selection [Haematopoietic and Lymphoid tissue];
Subtissue selection [Include All]; Histology Selection [Lymphoid
neoplasm]; subhistology selection [Include All]. The search
results were updated to the most recent values at the end
January 2016. To determine the more likely pathway members
contributing to tumorigenesis, a mutation frequency threshold
was set based on a study looking for oncogenic driver mutations
in Chronic Lymphocytic Leukemia (CLL) (Wang et al., 2011).
In that study, 88 Tumor samples were studied by exome and
whole genome sequencing. Oncogenic drivers were defined
as genes having mutation rates significantly higher than the
background taking into account sequence composition. The
gene identified with the lowest mutation frequency deemed
significant was ERK2 (MAPK1). In the gene set investigated in
the current analysis, ERK2 was found mutated 4 times out of
1508 samples (Table 1). Therefore, as mutations for ERK2 were
deemed significant oncogenic drivers in CLL and that the role
of the ERK1/2 MAPK pathway in tumor growth of B cells is
well established (Platanias, 2003; Rickert, 2013), the threshold of
significance in this analysis was set at 0.25%.
Distribution of Mutations in the TLR
Signaling Network
The TLR network architecture takes the shape of an hourglass,
with multiple TLRs feeding into a core signaling module
(MYD88-TRAF6-TAK1), before re-expansion downstream of
the activation of TAK1 (Figure 1). When examining mutations
identified in the TLR-network above the 0.25% threshold
(Table 1), 2 are found in the upper part of the hourglass
network (TLR2, and TLR5; 0.9% overall mutation frequency),
6 in the core network (MYD88, A20, ciap2, CYLD, TRAF3,
and Pellino 2; 33.4% overall mutation frequency) and 7 in the
downstream-activated signaling pathways (CBP, MYC, MKK1,
IKKβ, hnRNPA1, MKK2, and ERK2; 13.2% mutation rate).
Mutations that lead to activation of the upper part of the
TLR network (TLR + core signaling components) account
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TABLE 1 | Mutation frequency of TLR-signaling network components in lymphoid neoplasms.
Id. Alt Id No of mutations Samples tested % of mutations Most common non-silent mutation(s)
MYD88 MYD88 1754 7854 22.3 1584[L265P]
A20 TNFAIP3 214 3073 7.0 25[whole gene del]
CBP CREBBP 174 2605 6.7 12[R1446H]
cMyc MYC 40 1500 2.7 6[F138S]
ciap2 BIRC3 110 4173 2.6 12 [whole gene del]
MKK1 MAP2K1 40 1694 2.4 4[C121S]
TLR2 TLR2 8 1415 0.6 4[D327V]
CYLD CYLD 10 1832 0.5 6[whole gene del]
TRAF3 TRAF3 8 1673 0.5 2[whole gene del]
IKKβ IKBKB 8 1727 0.5 8[K171E]
TLR5 TLR5 5 1415 0.4 2[N96K]
PELI2 PELI2 5 1415 0.4 2[R154W]
hnRNPA1 HNRNPA1 4 1496 0.3 [S22T]; [E9K]; [T138S]
ERK2 MAPK1 4 1508 0.3 [D162N];[D291G];[R124H];[Y316F]
MKK2 MAP2K2 4 1589 0.3 2[Q60P]
ciap1 BIRC2 3 1415 0.2
TLR4 TLR4 3 1415 0.2
TLR8 TLR8 3 1415 0.2
MKK4 MAP2K4 3 1460 0.2
TLR6 TLR6 2 1415 0.1
pellino3 PELI3 2 1415 0.1
TAB3 TAB3 2 1415 0.1
ABIN1 TNIP1 2 1415 0.1
HOIP RNF31 2 1415 0.1
SMAD6 SMAD6 2 1415 0.1
TTP ZFP36 2 1415 0.1
TAB2 TAB2 2 1415 0.1
TLR1 TLR1 2 1415 0.1
ERK1 MAPK3 2 1423 0.1
IRAK4 IRAK4 2 1423 0.1
TPL2 MAP3K8 2 1423 0.1
JNK2 MAPK9 2 1423 0.1
MNK2 MKNK2 2 1423 0.1
IRAK1 IRAK1 2 1508 0.1
Genes with a mutation frequency >0.25 are in Yellow (upper and core TLR network) or Green (downstream effector pathways).
List of genes analyzed with: 1 mutation: TOLLIP, ATF2, CREB, SHARPIN, ECSIT, ELK1, MSK1, TBK1, TLR7, TAX1BP1, TAK1, MKK7, JNK1, p38α, IKKα, MSK2, IKKε, MAPKAPK2,
PELI1.
No mutation: ABIN2, TIRAP, TRAF6, TAB1, p105, MKK6, JNK3, p38β, ERK5, NEMO, IκBα, IκBβ, NFκB(p65), cJun, cFOS, eiF4E, HSP27, UBC13, Uev1a, TANK, IRAKM, TIFA,
SCF-βTRCP, HOIL1, hnRNPA0, MKK3, OTUL.
for more than a third of mutations found in lymphoid
neoplasms. This assumes that all these mutations only target
TLR-signaling, which is unlikely to be the case as regulators
of multiple pathways such as CYLD and A20 would impact
other pathways like the TNFR-activated pathway (Kovalenko
et al., 2003; Trompouki et al., 2003; Shembade et al., 2010)
or BAFF-R signaling in the case of ciap2 (Gardam et al.,
2011). But even when removing these components from the
equation more than a quarter of the mutations would be
hypothesize to favor enhanced signaling of the global TLR
signaling network. Looking at molecules assigned to effectors
of TLR signaling (bottom part of the hourglass) a striking
observation is that all of these molecules can be linked to ERK1/2
MAPK signaling (Figure 1). As was the case for ciap2, CYLD, and
A20, these downstream effectors are not specific to TLR signaling
and are targets of many other pathways. Nevertheless, they
provide clues as the likely arm of TLR-signaling contributing to
tumorigenesis.
TLRs-Linked to MYD88 Are More
Frequently Mutated than Those Linked to
TRIF
In the context of cancer biology, TLR-mediated activation of
MYD88 pro-inflammatory signaling is associated with tumor
formation and growth, whereas activation of the Type I IFN via
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FIGURE 1 | Components of the TLR signaling network frequently mutated in lymphoid neoplasms. The TLR signaling network is divided in three sections:
upper network, which comprises sensors, core network that is common to MYD88-dependent signaling and downstream effector pathways. Gene products that are
found frequently mutated in lymphoid neoplasms are highlighted in yellow (upper and core network) or green (downstream signaling effector pathways). In the core
network, the gray circles represent ubiquitin chains linked via Lysine 63 and the pale yellow hexagons represent linear ubiquitin chains. A pathway comprising all 77
network components investigated can be found in Supplementary Figure 1.
the TRIF adaptor has been associated with anti-tumor immunity
(Lin and Karin, 2007). In accordance with those data, not
only is MYD88 the most frequently mutated gene in lymphoid
neoplasms, but the TLRs harboring non-silent mutations above
the arbitrary threshold are those linked with MYD88 activation
(TLR2 and TLR5). Interestingly, these mutations map to the
extracellular domains of the TLRs and can be proposed to
favor dimerization. In contrast, no non-silent mutations are
reported in either TRIF, TRAM or TLR3, involved in type I IFN
signaling. TLR4 leads to activation of both MYD88 and TRIF-
dependent pathways. It would be interesting to check whether
any of the three mutations in TLR4 favors MYD88 signaling
to the detriment of TRIF signaling. These mutations could
promote association with MYD88 or signaling at the cell surface
instead of the endosome via decreased interaction with TRAF3
(Tseng et al., 2010). Two of the reported TRAF3 mutations are
whole gene deletions and another two are premature stop codon
that can be hypothesize to favor MYD88-dependent signaling
as shown with RNA interference against TRAF3 (Tseng et al.,
2010).
MYD88[L265P]: One Mutation to Rule
Them All
MYD88 is the most frequently mutated gene in lymphoid
neoplasm, all genes taken into account (Table 1). Moreover, one
mutation dominates: the nucleotide substitution L265P. This
mutant is present in 86–98% of patients with Waldenstrom’s
Macroglobulinemia (WM) (Treon et al., 2012; Jiménez et al.,
2013; Poulain et al., 2013). However, it is not restricted
to WM, with 29% of activated B-cell-like diffuse large B-
cell lymphoma (ABC-DLBCL) harboring the L265P mutation,
a subtype particularly difficult to cure. Overexpression of
MYD88[L265P] is linked with increase cell survival and NFκB
signaling (Yang et al., 2013). The mutant MYD88 activates
downstream signaling via allosteric TIR-domain oligomerization
(Avbelj et al., 2014) that activates TRAF6, IRAK1, and TAK1
(Ansell et al., 2014). Myddosome formation (oligomerization
of MYD88 and subsequent recruitment of accessories signaling
protein) is a key event linking TLR-dimerization upon ligand
binding to activation of effector pathways. Therefore, if TLR-
signaling contributes to lymphocyte tumorigenesis, it makes
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sense that one of the first step in the activation the signaling
cascade is the most frequently mutated event in lymphoid
neoplasms.
CYLD and A20: Negative Regulator of
MYD88-Dependent Signaling Have
Frequent Gene Deletions
CYLD and A20 act as negative regulators of TLR and TNFR
signaling. CYLD and TNFAIP3 are found frequently deleted
in lymphoid neoplasms, which contrasts with the presence of
single nucleotide substitutions more frequently found in positive
regulators of MYD88 signaling (Table 1). Loss of these negative
regulators would prolonged TLR-signaling and contribute to
tumor growth and survival. It is important to note that it is
difficult to determine whether the contribution of CYLD and A20
to tumor growth acts through TLR, TNFR, both TLR and TNFR
or other pathways.
Mutation Analysis of the TLR Downstream
Effector Pathways Points to Activation of
ERK1/2 as a Target of TLR-Driven
Lymphocyte Transformation
TLR-signaling leads to the activation of four major effector
pathways: the NFκB pathway and the three MAPK pathways,
ERK1/2, JNK, and p38 MAPK. The process of TLR-mediated
tumorigenesis may implicate all or some of these pathways.
Individually, each of these pathways have been linked to cancer,
and the discussion of these roles is beyond the scope of this
article. In the context of TLR-signaling, emphasis has been put
on NFκB activation, for both historical and technical reasons.
Nevertheless, theMAPK pathways may be important contributor
to tumorigenesis.
Interestingly, all of the seven genes identified carrying non-
silent mutations above the 0.25% threshold that are part of the
TLR effector pathways can be linked to the ERK1/2 MAPK
pathway (Figure 1). This suggests that the ERK1/2 pathway is
a path to tumorigenesis in TLR-driven lymphoid neoplasms.
This does not rule out a role for the JNK, p38 MAPK, or
NFκB, but simply mutations within these pathways are not
selected during clonal selection of tumor cells. Therefore, the
analysis of mutations found in the TLR network leads to the
formulation of the following hypothesis: “Inhibition of ERK1/2
MAPK activation would impair lymphocytes transformation
dependent on MYD88-activation.”
ACTIVATION OF ERK1/2 A CRITICAL
COMPONENT OF THE TRANSFORMATION
PROCESS IN LYMPHOID NEOPLASMS?
Constitutive ERK activity is a hallmark of many B-cell
malignancies (Platanias, 2003), consistent with the findings of
the mutational analysis presented in Section ‘Analysis of Somatic
Mutations Found in the TLR Signaling Network in Lymphoid
Neoplasm’ and a whole genome sequencing study in CLL (Wang
et al., 2011). Surprisingly, the upstream signals regulating ERK
activation in B-cells are poorly understood, as reported in a recent
article (Rickert, 2013).
The Protein Kinase Tumor Promoting
Locus 2 (TPL2) Is a Key Activator of
ERK1/2 Downstream of the IKK Complex
Activation of ERK1/2 can occur downstream of the classical RAS-
RAF-MKK1/2 pathway in response to growth factor activation
(Macdonald et al., 1993). However, ERK1/2 can also be activated
by another signaling pathway via the activation of the Tumor
Promoting Locus 2 (TPL2, also known as MAP3K8 or COT)
protein kinase (Dumitru et al., 2000). Activation of TPL2 requires
phosphorylation and degradation of NFκB1 p105 by the IκB
Kinase (IKK) complex (Beinke et al., 2004). Once activated TPL2
phosphorylates MKK1/2, direct upstream activators of ERK1/2.
This pathway is well established as essential to ERK1/2 activation
following TLR activation (Dumitru et al., 2000; Beinke et al.,
2004; Banerjee et al., 2006; Rousseau et al., 2008; Martel et al.,
2013). It is important to re-emphasize that following activation of
TLR-signaling, ERK1/2 activation will occur in parallel to NFκB
via a shared upstream activator. This means that experimental
data obtained with IKKβ inhibitors where the results were solely
assigned to NFκB activity may have overlooked an important
contribution of the ERK1/2 MAPK cascade. Interestingly, the
IKKβ [K171E] mutant identified in some lymphoid neoplasms
has greater activity toward NFκB activation but has not been
tested for its capacity to activate ERK1/2 (Kai et al., 2014). Based
on the critical role of IKKβ in activating TPL2, it is interesting
to speculate that this mutant will also lead to greater ERK1/2
activity.
MYD88[L265P] Leads to ERK1/2 Activation
via TPL2 in a Heterologous Expression
System
Heterologous expression of MYD88[L265P] in HEK293 cells,
not only activates the NFκB pathway (Figure 2A), but also the
ERK1/2 MAPK but only in the presence of TPL2 exogenous
expression (Figure 2B). This activation can be blocked with
an inhibitor of TPL2 (Figure 2B). Consistent with previously
published data on NFκB activation, MYD88[L265P] leads to
ERK1/2 phosphorylation in a TAK1 (MAP3K7) and MKK1/2-
dependent fashion (Figure 2B).
MKK1/2 Hot Spot for Resistance to RAF
and MEK (MKK) Inhibitors
MEK inhibitors have been of great interest as novel anti-
cancer agents. MEK162, showed improvement in progression-
free survival of patients with metastatic melanoma (Flaherty
et al., 2012) and is currently in phase II clinical trials for the
treatment of myeloid leukemia. The MKK1[C121S] mutation
leads to greater kinase activity and confers resistance to RAF and
MEK inhibitors (Wagle et al., 2011). Similarly, the MKK2[Q60P]
was found in tumor cells with sustained MAPK activation and
resistance to BRAF and MEK inhibitors (Villanueva et al., 2013).
Therefore, these mutations are not only oncogenic drivers but of
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FIGURE 2 | TPL2-mediates the MYD88[L265P] ERK MAPK activation in
HEK 293 cells. (A) Cells were grown to confluence, lysed with Promega’s
reporter buffer and subjected to luminescence analysis as previously
described. ***p < 0.005 vs. Myd88WT. All values are expressed as fold ±
S.E.M. from four different experiments. (B) Cells were serum starved overnight
and left untreated or pre-treated for 1 h with vehicle, NG25 (TAK1 inhibitor, 10
µM), C1 (TPL2 inhibitor, 2 µM), or MEK162 (MKK1/2 inhibitor, 1 µM). ERK1/2
phosphorylation was determined by immunoblotting. *p < 0.05 vs. to
Myd88WT and Myd88WT/L265P treated cells.
important concern in considering treatment options due to their
role in resistance to therapy.
The Complex Role of ERK1/2 Signaling in
Cellular Transformation
Oncogenic ERK1/2 activation leads to its translocation to
the nucleus and induction of transcription factor linked with
proliferation such as FOS, JUN, and MYC (Figure 1). However,
the role of ERK in tumorigenesis is not as simple as MYC-
driven cell proliferation. It is highly context dependent and
reflected by the fact that ERK1/2 activation is also linked
with growth arrest and differentiation in both normal and
transformed cells. Sustained ERK1/2 activation but not its
transient activity was linked with PC12 cell differentiation
(Traverse et al., 1992). Moreover, PMA-stimulation of the
K562 human leukemia cell line leads to growth arrest and
differentiation in a ERK1/2-dependent manner (Herrera et al.,
1998). Interestingly, acute ERK1/2 hyper-activation in tumors
by the oncogenic BRAF[V600E] mutant leads to tumor cell
senescence (Serrano et al., 1997; Michaloglou et al., 2005). This
phenomenon is not the result of ERK1/2 hyperactivity but the
induction of negative signaling feedback mechanisms acting as
tumor suppressors (Courtois-Cox et al., 2006). Therefore, the
capacity of cells to tolerate high level of ERK1/2 activity without
inducing senescence requires other transformation events, such
as the loss of negative feedback regulators. Supporting this
notion, acute activation of oncogenic signals in pre-B cells leads
to the majority of cells dying with only a fraction progressing to
malignant transformation (Shojaee et al., 2015).
In addition to its role in promoting cell proliferation when
escaping senescence, ERK1/2 MAPK activation is also linked
with increased cell survival and resistance to treatment like their
upstream activators MKK1/2. In hairy-cell leukemia, sustained
ERK1/2 activation promotes cell survival (Kamiguti et al., 2003).
Sustained BCR-signaling that prolong ERK1/2 and AKT(PKB)
signaling, increases the expression of the antiapoptotic protein
myeloid cell leukemia-1 (Mcl-1), promoting cell survival in CLL
(Petlickovski et al., 2005). Similarly, CXCR4 somatic mutations
frequently found in WM lead to sustained ERK1/2 and AKT
activation linked with resistance to the BTK inhibitor Ibrutinib
(Cao et al., 2015).
Although no experimental data is currently available for the
four ERK2 mutations identified in this analysis, it is interesting
to note that the tumor samples in which they have been
identified did not have mutations in MYD88 or other TLR-
related signaling network component. Coexistence of MYD88
and ERK2mutations would have undermined the theory that one
of the main outcome of MYD88 activation in tumor formation is
increase ERK1/2 activity.
MYC, CBP and hnRNPA1, Downstream
Targets of the ERK1/2 Pathway with
Potential Link with Tumorigenesis
The ERK1/2 MAPKs are Key Regulators of MYC
Expression and Function
Activation of MYC is associated with increased proliferation,
more aggressive disease and poorer outcomes in Richter’s
Transformation, a transformation of CLL into a clonally related
aggressive Diffuse Large B Cell Lymphoma (DLBCL) (Scandurra
et al., 2010). B-cell Receptor (BCR)-mediated expression of
MYC is regulated by ERK1/2-mediated phosphorylation of the
transcription factor ELK-1 (Yasuda et al., 2008). Moreover, it
has long been established that phosphorylation of MYC at
Ser62 by ERK1/2 promotes cellular transformation (Pulverer
et al., 1994). Therefore, the ERK1/2 MAPKs are involved at
two levels of MYC regulation contributing in both cases to
its transformation potential. Mutations in MYC, which also
include chromosomal rearrangements, lead to increase activity
that may render it independent of upstream signaling regulation.
Therefore, pharmacological strategies targeting upstream MYC
signaling in cells harboring MYC activation are hypothesized to
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be less effective than treatments inducing increase cell death via
antagonizing for example BCL-2 that cooperates with MYC in
transformation of pre-B cells (Vaux et al., 1988).
Loss of CBP Function Increases ERK1/2 Tumorigenic
Potential
CBP act as a transcriptional co-activator for numerous
transcription factors, including many oncogenes. In addition, it
can also act as an histone acetylase with p300 (another gene
frequently mutated in cancer) to dynamically regulate gene
expression. It is tempting to hypothesize that based on its
interaction with TFs known to be oncogenes, CBP promotes
tumor formation. However, most evidences point to CBP as a
tumor suppressor. This has been clearly demonstrated in mice,
where CBP heterozygotes developed hematologic malignancies
that were associated with the loss of the second CBP allele (Rebel
et al., 2002). Moreover, patients suffering from Rubinstein-Taybi
Syndrome, associated with mutations and deletions in CBP, have
an increased risk for leukemia (Jonas et al., 1978).
Interestingly, during persistent ERK1/2 activation, CBP
associates withMAPKAP-K1 (p90RSK) to promote growth arrest
and cell differentiation (Wang et al., 2003). Accordingly, in
the analysis presented in this paper, CBP is found frequently
deleted, which could be a permissive event in presence of
persistent ERK1/2 signaling to promote cellular growth instead
of arrest. This idea is supported by a study investigating relapsed
acute lymphoblastic leukemia (ALL). Non-synonymous somatic
mutations in CBP were found in conjunction with RAS signaling
pathway mutations within the same tumor samples (Mullighan
et al., 2011). The CBP mutations identified impaired histone
acetylation and transcriptional activity of CBP. These results
not only support the idea that loss of CBP activity enhances
ERK1/2-mediated transformation, but lend further strength to
the idea presented above about the importance of secondary
events impairing high or persistent ERK1/2 activation-induced
senescence.
hnRNPA1 Expression and Phosphorylation Occurs
Downstream of ERK1/2 Activation
In T lymphocytes, hnRNPA1, a TNFα AU-rich element
binding protein (Rousseau et al., 2002) is phosphorylated by
MNK1, a protein kinase activated by ERK1/2 and p38 MAPK
(Buxadé et al., 2005). Phosphorylation of hnRNPA1 contributes
to post-transcriptional regulation of TNFα (Buxadé et al.,
2005). Interestingly, recent evidences have highlighted roles
for genes involved in post-transcriptional regulation, such as
mRNA splicing, as oncogenic driver in CLL (Wang et al.,
2011). Moreover, MYC has been shown to increase hnRNPA1
expression leading in turn to higher expressing of pyruvate
kinase, contributing to aerobic glycolysis frequently observed
in tumor cells (David et al., 2010). In support for a role
of hnRNPA1 in lymphoid neoplasms, aberrant expression of
hnRNPA1 was described in acute leukemia (Choi et al., 2014).
Therefore, increased expression of hnRNPA1 driven byMYC and
its phosphorylation by MNK1 (two ERK1/2-dependent events),
or its aberrant expression resulting from gain-of-function
mutations, would increase pro-inflammatory gene synthesis and
aerobic glycolysis to contribute to tumorigenesis.
CONCLUSIONS
TLR-MYD88-IKKβ-TPL2-MKK1/2-ERK1/2,
a Key Path Cell to Transformation?
Previously published experimental data have established the
important contribution of MYD88-mediated signaling in a
number of B-cell malignancies (Ngo et al., 2011; Treon et al.,
2012; Wang et al., 2014). This is further supported by the
mutational analysis presented in this hypothesis and theory
article. Moreover, by looking at the frequency of gene mutations
downstream ofMYD88 activation, the ERK1/2MAPK pathway is
highlighted as a potential key effector pathway of tumorigenesis
via activation of downstream targets such MYC and hnRNPA1.
The overall outcome of this TLR-mediated signaling would
be at least two fold: (1) increased in cell proliferation via
MYC activation and anaerobic glycolysis (2) enhanced pro-
inflammatory signaling, in particular the expression of TNFα,
which would contribute to promote changes in the tumor
microenvironment favoring tumor growth.
Limitations of the Analysis
There are a number of limitations to the current analysis.
First, for a number of mutations identified, no experimental
data is available to support their role in modifying TLR
signaling. Moreover, these mutations were mostly considered
in isolation from each other. But as discussed in the ERK1/2
and CBP sections, tumor samples have multiple mutations
that may act together in order to promote tumorigenesis.
Furthermore, lymphoid neoplasms are numerous, affecting T and
B lymphocytes at different stages of their differentiation. Some
factors play more important roles in one disease over the other,
such as MYD88[L265P] in WM, or in pre-B cells vs. mature B
cells (Rickert, 2013). Finally, mutations may have different roles
in the tumor microenvironment vs. cells grown in tissue culture.
The tumor microenvironment is likely playing an important
role in understanding the breadth of impact that inflammation
has on tumorigenesis, particularly related to TLR-mediated pro-
inflammatory signaling.
Testing the Hypothesis in Waldenstrom’s
Macroglobulinemia
A number of hypothesis have been formulated along the way,
but the overarching one would be that inhibition of ERK1/2
MAPK activation would prevent tumor growth downstream of
MYD88[L265]. In the context of MYD88 driven tumorigenesis, a
particularly attractive target would be the protein kinase TPL2,
which should abrogate excess ERK signaling. Pharmacological
inhibitors have been developed that target TPL2 as shown in
Figure 2B, and it would be highly interesting to test these in
a more physiologically relevant setting than an heterologous
expression system. Since WM tumor cells have an overwhelming
presence of MYD88[L265P] mutations, they represent an
excellent model to test the hypothesis put forth in this article.
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EXPERIMENTAL PROCEDURES
Materials
The TAK1 inhibitor NG25 and the TPL2 inhibitor Compound 1
were kindly provided by Professor Sir Philip Cohen (MRC PPU,
University of Dundee, UK). The MKK1/2 inhibitor MEK162
(Binimetinib) was purchased from Selleck Chemicals (Houston,
TX, USA).
ERK1/2 Immunoblotting
100,000 HEK293TLR5 cells (Invivogen, San Diego, USA, #HKB-
HTLR5) were seeded in a 24-wells plate and transfected
with 200 ng of pCDNA3.1-TPL2 and 800 ng of pCDNA3.1-
Myd88 or the empty vector for 48 h using polyethylenimine
(PEI). Cells were grown to confluence, lysed and lysates
were subjected to SDS-PAGE. Quantitative analysis graph was
obtained with the signal intensity of an antibody recognizing the
phosphorylated forms of ERK1/2 at Thr202/Tyr204 normalized
to the signal obtained with antibody that recognizes all forms
of ERK1/2.
NFκB Luciferase Assay
Cells were transfected with 200 ng of pGL4.28-NF-κB and a
combination of varying amounts of pCDNA3.1-Myd88 WT
and/or pCDNA3.1-Myd88 L265P for a total of 1000 ng of
DNA per transfection. Cells were grown to confluence, lysed
with Promega’s reporter buffer and subjected to luminescence
analysis.
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